Theresa Barnes

Lead Consultant for Rheumatology

Theresa is lead consultant for rheumatology at the Countess of Chester Hospital. She has a general rheumatology practice and has special interests in biologic drug delivery, systemic sclerosis and basic laboratory research.

Qualifications

MBChB, BMedSci, MRCP, PhD.

Overview

She is deputy lead for the research and innovation committee at the Countess of Chester Hospital. She has an expanding portfolio of clinical rheumatology research including clinical trials work involving biologic drugs.

Theresa completed her PhD at the University of Liverpool funded by a MRC Clinical Research Fellowship and this work involved examining the role of the innate immune system in Systemic Sclerosis.

Teaching

Theresa has extensive experience in teaching undergraduate and postgraduate medical education.

She mentors GPs and pharmacists undertaking postgraduate diplomas in Rheumatology.

She is mentor for allied professionals undertaking masters qualifications.

She regularly delivers updates on Rheumatology practice for GPs.

She has many years of experience in lecturing to undergraduate medical and paramedical students at the University of Liverpool and now at Chester University.

She has been a PBL tutor for medical students at the University of Liverpool.

She has extensive experience in bedside teaching and PACES teaching for postgraduate doctors.

She has convened a special study module entitled “Management of severe rheumatoid arthritis” for 3 undergraduate medical students twice a year 2008-2011.

Research

Theresa has an expanding portfolio of clinical trials as a principal investigator. The trials focus on novel biologic drugs for rheumatology conditions and novel uses for existing biologic drugs.

She has special interests in systemic sclerosis and biologic drug delivery and has developed specialist clinics in systemic sclerosis and refractory inflammatory arthritis, which help to deliver excellent and consistent pathways of care and serve to aid recruitment into clinical trials and research studies.

In terms of laboratory research I have experience in leukocyte and endothelial cell biology and am developing an interest in microparticle biology particularly as it relates to cross talk between leukocytes and endothelial cells and it’s role in propagating inflammation and cardiovascular risk in rheumatological conditions.

Published work

Peer reviewed abstracts:

Wig S. Chan M. Barnes T  Bruce I.Eculizumab in refractory catastrophic anti-phospholipid syndrome.  Rheumatology. 2015.

Bishop K, Winget C, Cross A, Barnes T, Hawkes J, Moots R, Logan J, Edwards S. Microparticle microRNAs correlate with disease activity in rheumatoid arthritis and may play a significant role in pathogenesis. Rheumatology 2014; 53 (suppl 1): i148.

Barnes T, Anderson M, Spiller D, Edwards S, Moots R. Neutrophil reactive oxygen species generation in systemic sclerosis. Ann Rheum Dis 2010;69(Suppl3):242.

Barnes T, Spiller D, Anderson M, Edwards S, Moots R. Systemic sclerosis serum increases endothelial cell apoptosis and activation in neutrophil-endothelial cell co-cultures: A role for interleukin-6. Clinical and Experimental Rheumatology 2010: 37.

Barnes T, Hodgson R, Dawson J, Goodson N, Anderson M. Gastrointestinal blood flow in systemic sclerosis. Rheumatology 2008; 47(suppl 2): ii294.

Barnes T, Cross A, Naylor E, Anderson M, Edwards S, Moots R. Neutrophil cytoskeletal abnormalities in systemic sclerosis. Rheumatology 2008; 47(suppl 2): ii304.

Barnes T, Gliddon A, Dore C, Moots R, Maddison P. Predicting pulmonary artery hypertension in patients with systemic sclerosis. Arthritis and Rheumatism 2007: ii19

Hodgson R, Grainger A, Barnes T, Connolly S, O’Connor P, Moots R. Dynamic contrast enhanced MRI of bone marrow oedema in rheumatoid arthritis shows an early response to anti-TNF therapy. Arthritis and Rheumatism 2007: ii651.

Barnes T, Ward D, Anderson M, Rees H, Moots R, Edwards S. Proteomic studies suggest that neutrophils are activated in systemic sclerosis. Arthritis and Rheumatism 2006; 54(9 Suppl): ii1846.

Barnes T,  Gliddon A, Dore C, Moots R, Maddison P. Von Willebrand Factor as a Biomarker in Systemic Sclerosis. Arthritis and Rheumatism 2005; 52(Suppl):ii1572.

Barnes T, Abernethy V, Novak J, Mulvey E, Over K. Post operative complications in patients on anti-TNF therapies: Results from the Merseyside anti-TNF audit. Rheumatology 2005; 44(Suppl 1): ii85.

Barnes T, Bucknall R, Fraser W. Vitamin D deficiency in SLE. Rheumatology 2005; 44(Supp; 1): ii349.

Barnes T, Abernethy V. Are all anti-TNF drugs equal? Results of Mersey Biologics audit. Rheumatology 2004; 43 (Suppl 2): ii39.

Barnes T, Gupta V, Tunn E, Bucknall R, Nelson K. Aggressive treatment of rheumatoid arthritis for the busy clinician. Rheumatology 2004; 43(Suppl 2): ii147.

Barnes T, Daroszewska A, Fraser W and Bucknall R. Bone turnover in untreated Polymyalgia Rheumatica. Rheumatology 2003; 42(Suppl 1): 114.

Prabhakar E., Barnes T, and Spruce A. E. Labile sodium current expression in Xenopus embryonic myocytes. Proceedings of the Physiological Society Oxford meeting 11-14 July. 1995; p228P, PC96.

 

Publications

  1. Baseline von Willebrand factor predicts the development of pulmonary artery hypertension in systemic sclerosis. Barnes TC, Gliddon AE, Doré CJ, Maddison P, Moots RJ and the QUINs trial study group. Rheumatology 2012 Sep; 51(9): 1606-9.
  2. Neutrophil derived reactive oxygen species in systemic sclerosis. Barnes TC, Anderson ME, Edwards SW, Moots RJ. Rheumatology 2012 Jul; 51(7): 1166-9.
  3. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy and fibrosis in systemic sclerosis. Barnes TC, Anderson ME, Moots RJ. Int J Rheumatol 2011: 721608. Epub 2011 Sep 20.
  4. Relative α1-antitrypsin deficiency in systemic sclerosis. Barnes TC, Cross A, Anderson ME, Edwards SW, Moots RJ. Rheumatology 2011 Aug; 50(8): 1373-8.
  5. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin-6 trans-signalling: a novel target for systemic sclerosis? Barnes T, Spiller D, Anderson ME, Edwards SW, Moots RJ. Ann Rheum Dis 2011; 70(2): 366-372.
  6. Targeting oncostatin M in the treatment of rheumatoid arthritis. Barnes T, Moots RJ. In: New Therapeutic Targets in Rheumatoid Arthritis. (Tak P-P. Ed.) Birkhauser. 2009.
  7. Changes underlying the dynamic contrast-enhanced MRI response to treatment in rheumatoid arthritis. Hodgson RJ, Barnes T, Connolly S, Eyes B, Campbell RS, Moots R. Skeletal Radiol. 2008 Mar; 37(3):201-7.
  8. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Gliddon AE, Doré CJ, Black CM, McHugh N, Moots R, Denton CP, Herrick A, Barnes T, Camilleri J, Chakravarty K, Emery P, Griffiths B, Hopkinson ND, Hickling P, Lanyon P, Laversuch C, Lawson T, Mallya R, Nisar M, Rhys-Dillon C, Sheeran T, Maddison PJ. Arthritis Rheum. 2007 Nov; 56(11):3837-46.
  9. Dynamic contrast enhanced MRI of bone marrow oedema in rheumatoid arthritis. Hodgson R, Grainger A, O'Connor P, Barnes T, Connolly S, Moots R. Ann Rheum Dis. 2008 Feb;67(2):270-2.
  10. Pharmacokinetic modeling of dynamic contrast-enhanced MRI of the hand and wrist in rheumatoid arthritis and the response to anti-tumor necrosis factor-alpha therapy. Hodgson RJ, Connolly S, Barnes T, Eyes B, Campbell RS, Moots R. Magn Reson Med. 2007 Sep;58 (3):482-9.
  11. Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol. Barnes T, Moots R. Int J Nanomedicine. 2007; 2(1):3-7.
  12. Therapeutic targeting of cytokines. Barnes T, Goodacre J, Moots RJ. Cytokine. 2006 Aug; 35(3-4):217-9.
  13. Neutrophil apoptosis in rheumatoid arthritis is regulated by local oxygen tensions within joints. Cross A, Barnes T, Bucknall RC, Edwards SW, Moots RJ. J Leukoc Biol. 2006 Sep; 80(3):521-8.
  14. Cytokine medicines in clinical practice: current issues. Barnes T, Moots RJ, Goodacre J. Cytokine. 2005 Oct 21; 32(2):62-6. Epub 2005 Sep 26.
  15. Second International Conference on Cytokine Medicines. Barnes T, Goodacre J, Moots RJ. Expert Opin Biol Ther. 2005 Sep; 5(9):1255-8.
  16. Vitamin D deficiency in a patient with systemic lupus erythematosus. Barnes TC, Bucknall RC. Rheumatology (Oxford). 2004 Mar; 43(3):393-4.
  17. Bone turnover in untreated polymyalgia rheumatica. Barnes TC, Daroszewska A, Fraser WD, Bucknall RC. Rheumatology (Oxford). 2004 Apr; 43(4):486-90.
  18. A neural influence on the appearance of sodium current in Xenopus embryonic myocytes. Prabhakar E, Barnes T, Spruce AE. Neurosci Lett. 1996 Apr 5; 207(3):203-5.